title: Hypersensitivity reactions to etoposide phosphate.
abstract: Etoposide phosphate is a prodrug of intravenous etoposide recommended for use in patients with demonstrated allergy to etoposide. We have previously published a case series comprising six patients who were successfully treated with etoposide phosphate following preceding etoposide hypersensitivity. In this new paper we now present the cases of two patients who had allergic reactions to both etoposide and etoposide phosphate. As such, we suggest that whilst most patients with etoposide hypersensitivity can safely be treated with etoposide phosphate, a small number are at risk of an additional allergic reaction to etoposide phosphate. Patients being treated for the first time with etoposide phosphate after etoposide allergy should receive their first dose under medical supervision.
authors.affiliation: Department of Medical Oncology, Charing Cross Hospital, London, UK.
authors.forename: Khrishanthne
authors.initials: K
authors.lastname: Sambasivan
authors.forename: Sarah
authors.initials: S
authors.lastname: Mahmoud
authors.forename: Arwa
authors.initials: A
authors.lastname: Kokache
authors.forename: Michael
authors.initials: M
authors.lastname: Seckl
authors.forename: Philip
authors.initials: P
authors.lastname: Savage
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000208:ethnology*; D005047:Etoposide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D009943:Organophosphorus Compounds; C061400:etoposide phosphate; D005047:Etoposide
keywords: Hypersensitivity; allergy; etoposide phosphate; germ cell tumour